NCT07086651View on ClinicalTrials.gov

A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)

RecruitingOBSERVATIONAL
Enrollment

1,300

Participants

Timeline

Start Date

July 21, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Metastatic Castration Sensitive Prostate Cancer (mCSPC)Cancer of the ProstateProstate NeoplasmsProstate Cancer
Interventions
DRUG

Enzalutamide

As provided in real-world setting

DRUG

Apalutamide

As provided in real-world setting

Trial Locations (1)

10001

RECRUITING

Pfizer Inc, New York

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

Astellas Pharma Inc
All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

lead

Pfizer

INDUSTRY

NCT07086651 - A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC) | Biotech Hunter | Biotech Hunter